The HC Wainwright Initiates Coverage on ZIOPHARM Oncology Inc. (ZIOP)

The HC Wainwright Initiates Coverage on ZIOPHARM Oncology Inc. (ZIOP)

Several other research firms have also weighed in on ZIOP. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Griffin Securities reiterated a “buy” rating and issued a $23.00 price objective (up previously from $21.00) on shares of ZIOPHARM Oncology in a research note on Friday, February 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. ZIOPHARM Oncology currently has an average rating of “Hold” and an average price target of $11.00.

HC Wainwright initiated coverage on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) in a report released on Thursday. The brokerage set a “buy” rating and a $9.50 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 57.55% from the stock’s previous close.

Shares of ZIOPHARM Oncology (ZIOP) opened at 6.03 on Thursday. ZIOPHARM Oncology has a 52 week low of $4.45 and a 52 week high of $7.88. The stock’s market capitalization is $788.13 million. The stock’s 50 day moving average is $6.92 and its 200 day moving average is $6.44.

Several hedge funds and other institutional investors have recently made changes to their positions in ZIOP. National Planning Corp raised its position in shares of ZIOPHARM Oncology by 8.7% in the fourth quarter. National Planning Corp now owns 32,093 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,569 shares during the period. Teachers Advisors LLC raised its position in shares of ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 3,699 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of ZIOPHARM Oncology by 4.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 88,717 shares of the biotechnology company’s stock valued at $562,000 after buying an additional 3,886 shares during the period. American International Group Inc. raised its position in shares of ZIOPHARM Oncology by 7.1% in the first quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock valued at $475,000 after buying an additional 4,951 shares during the period. Finally, Vident Investment Advisory LLC raised its position in shares of ZIOPHARM Oncology by 5.8% in the fourth quarter. Vident Investment Advisory LLC now owns 114,980 shares of the biotechnology company’s stock valued at $615,000 after buying an additional 6,260 shares during the period. Institutional investors own 41.26% of the company’s stock. ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ZIOP”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment